Abstract：【Objective】To investigate the effects of liraglutide on levels of CA19-9 (carbohydrate antigen 19-9), CA724 (carbohydrate antigen 724), CEA (carcinoembryonic antigen) and serum ferritin (SF) in patients with type 2 diabetes mellitus patients with abnormal bone mass.【Methods】A total of 182 patients with type 2 diabetes combined with bone abnormalities and who received treatment in the Department of Endocrinology in our hospital from December 2015 to March 2017 were randomly divided into the observation group and the control group, with 91 cases in each group. Patients of two groups of were given dietary adjustments, exercise intervention and insulin glargine intensive treatment. According to blood glucose levels, patients in the control group received metformin treatment and patients in the observation group received liraglutide treatment. Both groups were treated for at least 3 months. The fasting blood glucose (FPG), 2 hour postprandial blood glucose (2hPG), glycosylated hemoglobin (HbA1c) and fasting insulin (FINS) levels before and after treatment were compared between the two groups of patients. Meanwhile, the changes in tumor markers and SF levels before and after treatment were compared between the two groups as well.【Results】Before treatment, there was no significant difference in FPG, 2hPG, HbA1c, and FINS levels between the two groups (P>0.05). After treatment, the FPG, 2hPG, HbA1c, and FINS levels in the two groups of patients were significantly lower. The levels of 2hPG and FINS in the observation group were significantly lower than those of the control group; the difference were with statistically significant (P<0.05). Levels of CA19-9, CA724, CEA and SF showed no significant differences before treatment (P>0.05). However, after treatment, they were significantly decreased in both groups. CA19-9, CA724, CEA and SF levels in the observation group after treatment were significantly lower than those of the control group. The differences were statistically significant (P<0.05).【Conclusion】Liraglutide can effectively reduce blood glucose levels and improve insulin sensitivity in patients with type 2 diabetes mellitus complicated with abnormal bone mass. It can significantly reduce the levels of CA19-9, CA724, CEA and SF as well. Thus, it may reduce the risk of diabetic complications and occurrence of malignant tumor.
赵海霞,吴会玲,王新民,段立志. 利拉鲁肽对2型糖尿病合并骨量异常患者CA19-9、CA724、CEA及SF的影响[J]. 医学临床研究, 2018, 35(3): 428-431.
ZHAO Hai-xia, WU Hui-ling, WANG Xin-min, et al. Effects of Liraglutide on CA19-9, CA724, CEA and SF in Type 2 Diabetic Patients with Bone Abnormalities. JOURNAL OF CLINICAL RESEARCH, 2018, 35(3): 428-431.
2018, Vol. 35 
